Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study

Emerging Microbes and Infections

Xiaojing Dong¹  Jingchuan Zhong¹  Xiaoying Gu¹  Jiuyang Xu¹  Xiaohui Zou¹  Bin Cao¹  Yeming Wang¹  Ying Wang¹  Liang Kang²  Hong Chen³  Chao Wu⁴  Yongfeng Hu⁵  Conghui Wang⁶  Guohui Fan⁶  Qi Jin⁶  Haibo Li⁶  Jianwei Wang⁶  Linghang Wang⁶  Li Guo⁶  Lili Ren⁶  Lianlian Han⁶  Geng Wang⁷ 

[1] Peking Union Medical College, Beijing, People’s Republic of China;Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China–Japan Friendship Hospital, Beijing, People’s Republic of China;Emergency Department of Infectious Diseases of Beijing Ditan Hospital, Capital Medical University, Beijing, People’s Republic of China;Institute of Clinical Medical Sciences, China–Japan Friendship Hospital, Beijing, People’s Republic of China;Jin Yin-tan Hospital, Wuhan, People’s Republic of China;;NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences &The Second Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China;

关键词: Cross-reactivity;    antibody;    HCoV-OC43;    SARS-CoV-2;    disease severity;   

DOI  :  10.1080/22221751.2021.1905488

来源: DOAJ

【 摘 要 】

Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63, and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titres mounted until days 22–28, whereas HCoV-OC43 antibody titres increased until days 15–21 and then plateaued until day 46. However, IgG titres against HCoV-NL63, −229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titres were significantly higher in patients with severe disease than those in mild patients at days 1–21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1–10 PSO, HCoV-OC43 S-IgG titres correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients.

【 授权许可】

Unknown